Diverse approaches for the enhancement of oral drug bioavailability

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 4, 2011, Pages 185-209

  Fasinu, Pius ^a   Pillay, Viness ^a   Ndesendo, Valence M K ^a   Du Toit, Lisa C ^a   Choonara, Yahya E ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

absorption; bioavailability; cytochrome P450; efflux transporters; enzymes; inhibitors; P glycoproteins; permeation enhancers; poorly water soluble drugs; pre systemic metabolism

Indexed keywords

ALENDRONIC ACID; AMPIROXICAM; AMPRENAVIR; ATORVASTATIN; BROMOCRIPTINE; CALCIUM PHOSPHATE; CLODRONIC ACID; CYCLODEXTRIN; CYTARABINE; DOMPERIDONE; DOXORUBICIN; DRUG ADDITIVE; DRUG VEHICLE; EMULSIFYING AGENT; ETIDRONIC ACID; FOSAMPRENAVIR; GABAPENTIN ENACARBIL; MELAGATRAN; NANOCRYSTAL; NANOPARTICLE; PACLITAXEL; PENETRATION ENHANCING AGENT; PIROXICAM; PRODRUG; SILICON DERIVATIVE; SOLUBILIZER; TENOFOVIR; TENOFOVIR DISOPROXIL; UNINDEXED DRUG; XIMELAGATRAN;

ARTICLE; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG SOLUTION; GASTROINTESTINAL HEMORRHAGE; HUMAN; NANOEMULSION; NANOTECHNOLOGY; SUSPENSION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; PRODRUGS; SOLUBILITY;

EID: 79955051472     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.750     Document Type: Article

References (173)

1. Chain PCS, Holford NHG,. Drug treatment effects on disease progression. Ann Rev Pharmacol Toxicol 2001; 41: 625-659. (Pubitemid 32385901)
2. Smolen VF, Weigand WA,. Drug bioavailability and pharmacokinetic analysis from pharmacological data (Scientific Commentary). J Pharmacol Biopharm 1973; 1: 329-336.
3. Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, Yamashita S,. Site of absorption after oral administration: Assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci 2006; 29: 240-250. (Pubitemid 44602413)
4. Ghilzai MK,. Advances in the delivery of large-size drug molecules. Innov Pharm Technol 2004; 102-108.
5. Hamman JH, Enslin GM, Kotze AF,. Oral delivery of peptide drugs. Biodrugs 2005; 19: 165-177.
6. Leonard TW, Lynch J, McKenna MJ, et al,. Promoting absorption of drugs in human medium chain fatty acid-based solid dosage forms: GIPET. Expert Opin Drug Deliv 2006; 3: 685-692. (Pubitemid 44383494)
7. Majundar S, Mitra A,. Chemical modification and formulation approaches to elevated drug transport across cell membranes. Expert Opin Drug Deliv 2006; 3: 511-527.
8. Hellriegel ET, Bjornsson TD, Hauck WW,. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 1996; 60: 601-607. (Pubitemid 27025907)
9. Aungst BJ,. Intestinal permeation enhancers. J Pharm Sci 2000; 89: 429-442.
10. van de Waterbeemd H,. In Oral Drug Absorption, Prediction and Assessment, Dressman J, Lennernas H, (eds). Marcel Dekker, Inc.: New York, 2000; 38.
11. Pang KS,. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette review series). Drug Metab Dispos 2003; 31: 1507-1519. (Pubitemid 37466919)
12. Hamman JH, Demana PH, Olivier EI,. targeting receptors, transporters and site of absorption to improve oral drug delivery. Drug Target Insights 2007; 2: 71-81.
13. Morishita M, Peppas NA,. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 2006; 11: 905-910. (Pubitemid 44403178)
14. Aviva E, Gershon G,. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Del Rev 2000; 42: 175-195.
15. Cremers SC, van Hogezand R, Banffer D, et al,. Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease. Osteopor Int 2005; 16: 1727-1730. (Pubitemid 41790882)
16. Lambrinoudaki I, Christodoulakos G, Botsis D,. Women's health and disease: gynaecologic, endocrine, and reproductive issues. Ann NY Acad Sci 2006; 1092: 397-402.
17. Reinoso RF, Sanchez Navarro A, Garcia MJ, Prous JR,. Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2002; 24: 593-613. (Pubitemid 36109399)
18. Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR,. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2003; 24: 457-481. (Pubitemid 37203702)
19. Buse J,. Statin treatment in diabetes mellitus. Clin Diabet 2003; 21: 168-172.
20. Degim GL, Acarturk F, Erdogan D, Demirez Lortlar N,. Transdermal administration of bromocriptine. Biol Pharm Bull 2003; 26: 501-505. (Pubitemid 39663596)
21. Turner JV, Glass BD, Agatonovic-Kustrin S,. Prediction of drug bioavailability based on molecular structure. Anal Chim Acta 2003; 485: 89-102. (Pubitemid 36577477)
22. Niemi R, Turhanen P, Vepsalainen J, Taipale H, Jarvinen T,. Bisphosphonate prodrugs: synthesis and in vitro evaluation of alkyl and acyloxymethyl esters of etidronic acid as bioreversible prodrugs of etidronate. Eur J Pharm Sci 2000; 11: 173-180. (Pubitemid 30479859)
23. Joseph NM, Sharma PK,. Cross-linked nanoparticles of cytarabine: encapsulation, storage and in vivo release. Afr J Pharm Pharmacol 2007; 1: 10-13.
24. Ahmad N, Keith-Ferris J, Gooden E, Abel T,. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 2006; 6: 571-576. (Pubitemid 44660947)
25. Sturgill MG, August DA, Brenner DE,. Hepatic enzyme induction with phenobarbital and doxorubicin metabolism and myelotoxicity in the rabbit. Cancer Invest 2000; 18: 197-205. (Pubitemid 30164149)
26. Dorne JLCM, Walton K, Renwick AG,. Human variability in CYP 3A4 metabolism and CYP 3A4-related uncertainty factors for risk assessment. Food Chem Toxicol 2003; 41: 201-224. (Pubitemid 35447872)
27. Tse FL, Jaffe JM,. Pharmacokinetics of PN 200-110 (Isradipine) a new calcium antagonist, after oral administration in man. Eur J Clin Pharmacol 1987; 32: 361-365. (Pubitemid 17077182)
28. Choi JS, Burm JP,. Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. Arch Pharm Res 2006; 29: 333-338.
29. Bennett M, Lucas V, Benna M, Hughes A, O'Donnell V, Wee B,. Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care. Palliat Med 2002; 16: 369-374.
30. Kharasch ED, Labroo R,. Metabolism of ketamine stereoisomers by human liver microsomes. Anaesthesiology 1992; 6: 1201-1207. (Pubitemid 23001132)
31. Manoir BD, Bourget P, Langlois M, et al,. Evaluation of the pharmacokinetic profile and analgesic efficacy of oral morphine after total hip arthroplasty. Eur J Anaesthesiol 2006; 23: 748-754. (Pubitemid 44195806)
32. Aquilonius SM, Eckernas SA, Hartvig P, Lindstrom B, Osterman PO,. Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Clin Pharmacol 1980; 18: 423-428. (Pubitemid 11247444)
33. Kleiman-Wexler RL, Adair CG, Ephgrave KS,. Pharmacokinetics of naloxone: an insight into the locus of effect on stress-ulceration. J Pharmacol Exp Ther 1989; 251: 435-438. (Pubitemid 20005581)
34. Finn A, Collins J, Voyksner R, Lindley C,. Bioavailability and metabolism of prochlorperazine administered via buccal and oral delivery route. J Clin Pharmacol 2005; 45: 1383-1390. (Pubitemid 41642441)
35. Clarke A, Jankovic J,. Selegiline orally disintegrating tablet in the treatment of Parkinson's disease. Exp Rev 2006; 3: 349-356. (Pubitemid 43881100)
36. Cossons VF, Fuseau E,. Mixed effect modelling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. J Pharmacokin Pharmacodyn 1999; 27: 149-171. (Pubitemid 29484767)
37. Jann MW, Shirley KL, Small GW,. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokin 2002; 41: 719-739. (Pubitemid 34948194)
38. Nakhat PD, Kondawar AA, Babla IB, Rathi LG, Yeole PG,. Studies on buccoadhesive tablets of terbutaline sulphate. Indian J Pharm Sci 2007; 69: 505-510.
39. Isohanni MH, Neuroven PJ, Olkkola KT,. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine. Basic Clin Pharmacol Toxicol 2006; 99: 168-172. (Pubitemid 44213946)
40. Panchagnula R, Thomas NS,. Biopharmaceutics and pharmacokinetics in drug research. Int J Pharm 2000; 201: 131-150. (Pubitemid 30394660)
41. Aungst BJ,. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 2006; 82: 979-987.
42. Matheny CJ, Lamb MW, Brouwer KLR, Pollack GM,. P-glycoprotein modulation: expression and function in tissues. Medscape Today 2009. [25 June 2009 ].
43. Hussain A, Arnold JJ, Khan MA, Ahsan F,. Absorption enhancers in pulmonary protein delivery. J Control Release 2004; 94: 15-24. (Pubitemid 37542374)
44. Takatsuka S, Kitazawa T, Morita T, Horikiri Y, Yoshino H,. Enhancement of intestinal absorption of poorly absorbed hydrophilic compounds by simultaneous use of mucolytic agent and non-ionic surfactant. Eur J Pharm Biopharm 2006; 62: 52-58. (Pubitemid 41736025)
45. Kawahara I, Kato Y, Suzuki H, et al,. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1,1- dimethylethanolaminocarbonyl)-4-[furo[2,3-b]pyridin-5-yl)methyl]piperazine-1-yl] (4)-hydroxy-2(R)-phenylmethylpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos 2000; 28: 1238-1243.
46. Vasikaran SD,. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 2001; 38: 608-623. (Pubitemid 33702268)
47. Legen I, Kracun M, Salobir M, Kerc J,. The evaluation of some pharmaceutically acceptable excipients as permeation enhancers for amoxicillin. Int J Pharm 2006; 308: 84-89. (Pubitemid 43097238)
48. Raoof AA, Ramtoola Z, Mckenna B, Yu RZ, Hardee G, Geary RS,. Effects of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. Eur J Pharm Sci 2002; 17: 131-138. (Pubitemid 35248266)
49. Grabovac V, Schmitz T, Forger F, Bernkop-Schnurch A,. Papain: An effective permeation enhancer for orally administered low molecular weight heparin. Pharm Res 2007; 24: 1001-1006. (Pubitemid 46675402)
50. Watt A, Morrison D,. Strategic and technical challenges for drug discovery. Drug Discov Today 2001; 6: 290-292. (Pubitemid 32194665)
51. Payghan S,. Potential of solubility and drug discovery development. Pharminfo.net. 2008. [Accessed 24 March 2009 ].
52. Naseem A, Olliff CJ, Martini LG, Lloyd AW,. Effects of plasma irradiation on the wettability and dissolution of compacts of griseofulvin. Int J Pharm 2004; 269: 443-450. (Pubitemid 38045307)
53. Gursoy RN, Benita S,. Self-emulsifying-drug delivery systems (SEDDS) for improved oral delivery of lipophilic drug. Biomed Pharmacother 2004; 58: 173-182. (Pubitemid 38479922)
54. Ward GH, Schultz RK,. Process-induced crystallinity changes in albusterosulfate and its effect on powder physical stability. Pharm Res 1995; 12: 773-779.
55. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E,. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 1998; 24: 1113-1128. (Pubitemid 28546092)
56. Longqin H,. The prodrug approach to better targeting. Current Drug Discovery 2004. [Accessed 25 March 2009 ].
57. Wong SM, Kellaway IW, Murdan S,. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm 2006; 317: 61-68. (Pubitemid 43866347)
58. Vasconcelos T, Samento B, Costa P,. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007; 12: 1068-1075. (Pubitemid 350186132)
59. Karavas E, Ktistis G, Xenakis A, Georgarakis E,. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. Eur J Pharm Biopharm 2006; 63: 103-114. (Pubitemid 43776203)
60. Muhrer G, Meier U, Fusaro F, Albano S, Mazzotti M,. Use of compressed gas precipitation to enhance the dissolution behaviour a poorly water-soluble drug: Generation of drug microparticles and drug-polymer solid dispersions. Int J Pharm 2006; 308: 69-83. (Pubitemid 43097237)
61. Pokharkar VB, Mandpe LP, Padamwar MN, Ambike AA, Mahadik KR, Paradkar A,. Development, characterization and stabilization of amorphous form of a low Tg drug. Powder Tech 2006; 167: 20-25. (Pubitemid 44215984)
62. Jang D, Jeong EJ, Lee H, Kim B, Lim S,. Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. Eur J Pharm Sci 2006; 28: 405-411. (Pubitemid 44038349)
63. Pouton CW,. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the Lipid Formulation Classification System. Eur J Pharm Sci 2006; 29: 278-287. (Pubitemid 44740131)
64. Porter CJH, Trevaski NL, Chaman WN,. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Disc 2007; 6: 231-248. (Pubitemid 46344627)
65. Wu C, Benet LZ,. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23. (Pubitemid 40558141)
66. Sunesen VH, Vedesdal R, Kristensen HG, Christup L, Mullertz A,. Effects of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci 2005; 24: 297-303. (Pubitemid 40283512)
67. Porter CJH, Pouton CW, Cuine JF, Chaman WN,. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Del Rev 2008; 60: 673-691.
68. Du Toit L, Pillay V, Choonara YE, Pillay S, Harillal S,. Patenting of nanopharmaceuticals in drug delivery: no small issue. Rec Pat Drug Del Form 2007; 1: 131-142.
69. Kaparissides C, Alexandridou S, Kotti K, Chaitidou S,. Recent advances in novel drug delivery systems. Journal of Nanotechnology Online 2006; 2: 1-11. DOI: 10.2240/azojono0111.
70. Saffie-Siebert R, Ogden J, Parry-Billings M,. Nanotechnology approaches to solving the problems of poorly water-soluble drugs. Drug Discovery World Summer 2005; 71-76. (Pubitemid 41015576)
71. High-intensity ultrasound creates hollow nanospheres and nanocrystals. Physorg.com 2005. [Accessed 25 March 2009 ].
72. Bean L., How nanotechnology has been applied to cancer treatment 2006. ...[Accessed 25 March 2009 ].
73. Loher S, Huber M, Stark WJ,. Biodegradable, nanoparticulate polymer fillers 2005. [Accessed 25 March 2009 ].
74. Lvov Y, Torchilin V, Agarwal A, Sawant R,. Sonication-assisted nanoencapsulation 2008. ... [Accessed 25 March 2009 ].
75. Miller OJ, Bernath K, Agresti J, et al,. Directed evolution by in vitro compartmentalization. Nat Meth 2006; 3: 561-570. (Pubitemid 43941775)
76. Safer nanoparticles spotlight tumors, deliver drugs. Physorg.com 2008. [Accessed 25 March 2009 ].
77. Filho NLD, Costa RM, Marangoni F, Pereira DS,. Nanoparticles of octakis[3-(3-amino-1,2,4-triazole)propyl]octasilsesquioxane as ligands for Cu(II), Ni(II), Cd(II), Zn(II), and Fe(III) in aqueous solution. J Coll Int Sci 2007; 316: 250-259.
78. Ahamed M, Karns M, Goodson M, et al., DNA damage response to different surface chemistry of silver nanoparticles in mammalian cells. Toxicol App Pharmacol 2008; 233: 404-410.
79. Maynard AD,. Nanotechnology: the next big thing, or much ado about nothing? Ann Occup Hyg 2007; 51: 1-12. (Pubitemid 46096390)
80. Oberdorster G, Oberdorster E, Oberdorster J,. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113: 823-839. (Pubitemid 40984181)
81. Patel RN,. Synthesis of chiral pharmaceutical intermediates by biocatalysis. Coord Chem Rev 2008; 252: 659-701.
82. Xu Y, Marron MT, Seddon E, et al,. 2,3-Dihydrowithaferin A-3β-O-sulfate, a new potential prodrug of withaferin A from aeroponically grown Withania somnifera. Bioorg Med Chem 2009; 17: 2210-2214.
83. Han H, Amidon GL,. Targeted prodrug design to optimize drug delivery. AAPS Pharmsci 2000; 2: 1-11.
84. Meyers CLF, Borch RF,. Activation mechanisms of nucleoside phosphoramidate prodrugs. J Med Chem 2000; 43: 4319-4327.
85. Napier MP, Sharma SK, Springer CJ, et al,. Antibody-directed prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. Clin Canc Res 2000; 6: 765-772. (Pubitemid 30159328)
86. Rautio J, Kumpulainen H, Heimbach T, et al,. Prodrugs: design and clinical applications. Nat Rev Drug Disc 2008; 7: 255-270. (Pubitemid 351324639)
87. Pang KS, Cherry WF, Terrell JA, Ulm EH,. Disposition of enalapril and its diacid metabolite, enalaprilat, in a perfused rat liver preparation. Presence of a diffusional barrier for enalaprilat into hepatocytes. Drug Metab Dispos 1984; 12: 309-313. (Pubitemid 15120549)
88. Hall VJ, Li J, Brundin P,. Restorative cell therapy for Parkinson's disease: A quest for the perfect cell. Sem Cell Dev Biol 2007; 18: 859-869. (Pubitemid 350138454)
89. Hu L,. The prodrug approach for better targeting 2004. [Accessed 26 March 2009 ].
90. Cundy KC, Branch R, Chenov-Rogan T, et al,. XP13512, a novel gabapentin prodrug: design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004; 311: 315-323.
91. Hu L,. Prodrugs: effective solution for solubility, permeability and targeting 2004. [Accessed 23 March 2009 ].
92. Lacombe O, Woodley J, Solleux C, et al,. Localization of drug permeability along the rat small intestine, using markers of the paracellular, transcellular and some transporter routes. Eur J Pharm Sci 2004; 23: 385-391. (Pubitemid 39573390)
93. Ali J, Hassan S, Ali M,. Formulation and development of gastroretentive drug delivery system for ofloxacin. Methods Findings Exp Clin Pharmacol 2006; 28: 433-441.
94. Drummer OH, Jarrott B,. The disposition and metabolism of captopril. Med Res Rev 2006; 6: 75-97.
95. Streubel A, Siepmann J, Bodmeier R,. Drug delivery to the upper small intestine window using gastro-retentive technologies. Curr Opin Pharmacol 2006; 6: 501-506.
96. Klausner EA, Lavy E, Stephensky D, et al., Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. J Clin Pharmacol 2003; 43: 711-720. (Pubitemid 36759148)
97. Terao T, Matsuda K, Shouji H,. Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55. J Pharm Pharmacol 2001; 53: 433-440. (Pubitemid 32396533)
98. Castrol B, Domingues V, Gameiro P, Lima JLFC, Oliveira A, Reis S,. Acid base properties and solubility of pindolol, diazepam and chlordiazepoxide in SDS micelles. Int J Pharm 1999; 187: 67-75. (Pubitemid 29435974)
99. Rosa M, Zia H, Rhodes T,. Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm 1994; 105: 65-70. (Pubitemid 24087674)
100. Deshpande AA, Rhodes CT, Shah NH, Malick AW,. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev Ind Pharm 1996; 22: 531-540.
101. Deshpande AA, Rhodes CT, Shah NH, Malick AW,. Development of a novel controlled-release system for gastric retention. Pharm Res 1997; 14: 815-819. (Pubitemid 27281680)
102. Whitehead L, Fell JT, Collett JH, Sharma L, Smith AM,. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Contr Rel 1998; 55: 3-12. (Pubitemid 28477559)
103. Singh B, Kim K,. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Contr Rel 2000; 63: 235-259.
104. Chawla G, Bansal A,. A means to address regional variability in intestinal drug absorption. Pharm Technol 2003; 27: 50-68. (Pubitemid 37101890)
105. Patel DM, Patel NM, Pandya NN, Jogani PD,. Gastroretentive drug delivery system of carbamazepine: formulation optimization using simplex lattice design: a technical note. AAPS Pharm Sci Tech 2007; 8: 1-5.
106. Shinde AJ, More HN,. Gastroretentive drug delivery system: an overview. 2008.
107. Garg S, Sharma S,. Gastroretentive drug delivery systems. Business Briefing; Pharmatech 2003; 160-166.
108. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F,. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Contr Rel 2005; 111: 1-18. (Pubitemid 43289989)
109. Murphy CS, Pillay V, Choonara YE, du Toit LC,. Gastroretentive drug delivery systems: current developments in novel system design and evaluation. Curr Drug Deliv 2009; 6: 451-460.
110. Ho P-C, Saville DJ,. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furacoumarins and related compounds. J Pharm Pharmaceut Sci 2001; 4: 217-227. (Pubitemid 34305597)
111. Eeckman F, Moës AJ, Amighi K,. Evaluation of a new controlled-drug delivery concept based on the use of thermoresponsive polymers. Int J Pharm 2002; 241: 113-125. (Pubitemid 34667072)
112. Atyabi F, Majzoob S, Iman M, Salehi M, Dorkoosh F,. In vitro evaluation and modification of pectinate gel beads containing trimethyl chitosan, as a multi-particulate system for delivery of water-soluble macromolecules to colon. Carbohydr Polym 2005; 61: 39-51. (Pubitemid 40774011)
113. Zeitoun AA, Dib JG, Mroueh M,. A comparative single dose bioequivalence study of two enteric coated aspirin brands among healthy volunteers. J Appl Res Clin Exp Ther 2006; 13: 3.
114. Somogyi AA, Bochner F, Hetzel D, Williams DB,. Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin. Pharm Res 1995; 12: 149-154.
115. Jung T, Kamm W, Breitenbach A, Kaiserling E, Xiao JX, Kissel T,. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 2000; 50: 147-160. (Pubitemid 30326694)
116. Chourasia MK, Jain SK,. Polysaccharides for colon targeted drug delivery. Drug Del 2004; 11: 129-148. (Pubitemid 38437082)
117. Chourasia MK, Jain SK,. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharmaceut Sci 2003; 6: 33-66. (Pubitemid 37207241)
118. Laila A, Asghar F, Chandran S,. Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J Pharm Pharmaceut Sci 2006; 9: 327-338. (Pubitemid 46614339)
119. Antonin KH,. Other methods in studying colonic drug absorption. In Colonic Drug Absorption and Metabolism, Bieck PR, (ed.). Marcel Dekker, Inc.: New York, 1993; 89-107.
120. Sinha VR, Kumria R,. Polysaccharides in colon-specific drug delivery. Int J Pharm 2001; 224: 19-38. (Pubitemid 32706482)
121. Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, Gazzaniga A,. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J Controlled Release 2001; 73: 103-110. (Pubitemid 32409351)
122. Cole ET, Scott RA, Connor AL, et al,. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm 2002; 231: 83-85.
123. Wahlqvist ML, Ball M,. Colon and its function. Food and Nutrition Book (2nd edn). New South Wales: Allen and Unwin, 2002; 235.
124. Ashford M, Fell J, Attwood D, Sharma H, Woodhead P,. Studies on pectin formulations for colonic drug delivery. J Contr Release 1994; 30: 225-232. (Pubitemid 24216836)
125. Sinha VR, Kumria R,. Colonic drug delivery: prodrug approach. Pharm Res 2001; 18: 557-564. (Pubitemid 32595781)
126. Sinha VR, Kumria R,. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003; 18: 3-18. (Pubitemid 36120550)
127. Gupta S,. P-glycoprotein expression and regulation. Drugs Aging 1995; 7: 19-29.
128. Ambudkar SV, Dey S, Hrycyna A, Ramachandra M, Pastan I, Gottesman MM,. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Ann Rev Pharmacol Toxicol 1999; 39: 361-398. (Pubitemid 29222564)
129. Hugger ED, Audus KL, Borchardt RT,. Effects of poly(ethylene)glycol on efflux transporter activity in CaCO-2 cell monolayers. J Pharm Sci 2002; 91: 1980-1990. (Pubitemid 36254934)
130. Borrel M, Pereira E, Fiallo M, Garnier-Suillerot A,. Analysis of multidrug transporter in living cells: inhibition of P-glycoprotein-mediated efflux of anthracyclines by ionophores. Metal-based Drugs 1994; 1: 175-182.
131. Juliano RL, Ling L,. A surface glycoprotein on modulating drug permeability in Chinese Hamster Ovary cell mutants. Biochem Biophys Acta 1976; 555: 152-162.
132. Schinkel AH, Kemp S, Dolle M, Rudenco G, Wagenaar E,. N-Glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem 1993; 268: 7474-7481. (Pubitemid 23105645)
133. Thiebut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I,. Cellular localisation of the Multidrug Resistance Gene Product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
134. Varma MVS, Ashokraj Y, Dey CS, Panchagnula R,. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharm Res 2003; 48: 347-359. (Pubitemid 36945333)
135. Varma MVS, Perumal OP, Panchagnula R,. Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr Opin Chem Biol 2006; 10: 367-373. (Pubitemid 44080650)
136. Pang KS, Weiss M, Macheras P,. Advanced pharmacokinetic models based on organ clearance, circulatory and fractal concepts. AAPS J 2007; 9: 268-283.
137. Bergheim I, Bode C, Parlesak A,. Distribution of cytochrome P450 2C, 2E1, 3A4 and 3A5 in human colon mucosa. BMC Clin Pharmacol 2005; 5: 4.
138. Li LY, Amidon GL, Kim JS, et al,. Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability. J Pharmacol Exp Ther 2002; 301: 586-593. (Pubitemid 34429971)
139. Heydel J, Leclerc S, Bernard P, et al., Rat olfactory bulb and epithelium UDP-glucuronosyl transferase 2A1 (UGT2A1) expression: in situ mRNA localization and quantitative analysis. Mol Brain Res 2001; 90: 83-92. (Pubitemid 32497175)
140. Sharma RA, Ireson CR, Verschoyle RD, et al,. Effects of dietary curcumin on glutathioneS-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 2001; 7: 1452.
141. Miki Y, Nakata T, Suzuki T, et al,. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J Clin Endocrinol Metab 2002; 87: 5760-5768. (Pubitemid 36034387)
142. Miki Y, Nakata T, Suzuki T, et al,. Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J Clin Endocrin Met 2002; 87: 5760-5768. (Pubitemid 36034387)
143. Ziegler TR, Fernandez-Estivariz C, Gu LH, Bazargan N, Umeakunne K,. Distribution of the H+/peptide transporter Pep T1 in human intestine: up-regulated expression in the colonic mucosa of patients with short-bowel syndrome. Am J Clin Nutr 2002; 75: 922-930. (Pubitemid 34441262)
144. Botka CW, Wittig TW, Graul RC, et al., Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. AAPS Pharm Sci 2000; 2.
145. Konishi Y, Kobayashi S,. Microbial metabolites of ingested caffeic acid are absorbed by the monocarboxylic acid transporter (MCT) in intestinal Caco-2 cell monolayers. J Agric Food Chem 2004; 52: 6418-6424.
146. Con D, Fong AKY, Lee R, et al,. Absorption of benzoic acid (BA) by segmental regions of the in situ perfused rat small intestine. Drug Metab Dispos 2001; 29: 1539-1547. (Pubitemid 33111586)
147. 3 on transporters and enzymes associated with bile acid homeostasis in rat liver. APPS J 2005; S2.
148. Liu S, Tam D, Chen X, Pang KS,. An unstirred water layer and P-glycoprotein barring digoxin absorption by the perfused rat small intestine preparation: induction studies with and without pregnenolone 16α-carbonitrile (PCN) induction. Drug Met Dispos 2006; 34: 1468-1479. (Pubitemid 44285387)
149. Mottino AD, Hoffman T, Jennes L, et al., Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 2000; 293: 717-723. (Pubitemid 30417835)
150. Gotoh Y, Suzuki H, Kinoshita S, et al., Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. J Pharmacol Exp Ther 2000; 292: 433-439. (Pubitemid 30026403)
151. Xue Y, Yap CW, Sun LZ, Cao ZW, Wang JF, Chen YZ,. Prediction of P-glycoprotein substrates by a support vector machine approach. J Chem Inf Comput Sci 2004; 44: 1497-1505.
152. From MF,. The influence of MDR1 polymorphisms on p-glycoprotein expression and function in humans. Adv Drug Del Rev 2002; 54: 1295-1310.
153. Johnson WW,. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: Modulation of chemotherapy resistance. Methods Find Exp Clin Pharmacol 2002; 24: 501.
154. Yang S, Gursoy RN, Lambert G, Benita S,. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 2004; 21: 261-270. (Pubitemid 38221971)
155. Breedveld P, Beijnen JH, Schellens JHM,. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. TRENDS Pharmacol Sci 2006; 27: 17-24. (Pubitemid 43063120)
156. Woo JS, Lee CH, Shim CK, Hwang S,. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 2003; 20: 24-30. (Pubitemid 36152913)
157. Zhu H, Wang J, Markowitz JS, Donovan JL, Gibson BB, DeVane CL,. Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology 2007; 32: 757-764. (Pubitemid 46426181)
158. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P,. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci 1999; 88: 1067-1072. (Pubitemid 29480601)
159. Shapiro AB, Ling V,. Effects of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. Biochem Pharmacol 1997; 53: 587-596. (Pubitemid 27149553)
160. Hugger ED, Novak BL, Burton PS, Audus KL, Bochardt RT,. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002; 91: 1991-2002. (Pubitemid 36254935)
161. Collnot E-M, Baldes C, Wempe MF, et al,. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Contr Rel 2006; 111: 35-40. (Pubitemid 43289992)
162. Guéraud F, Alary J, Costet P,. In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2-nonenal, using PPARα-deficient mice. J Lipid Res 1999; 40: 152-159. (Pubitemid 29022597)
163. Glue P, Clement RP,. Cytochrome P450 enzymes and drug metabolism-basic concepts and methods of assessment. Cell Mol Neurobiol 2004; 19: 309-323.
164. Nelson DR, Kamataki T, Waxman DJ, et al,. The P450 superfamily; update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12: 1-51. (Pubitemid 23064489)
165. Quintieri L, Palatini P, Nassi A, Ruzza P, Floreani M,. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochem Pharmacol 2008; 75: 1426-1437.
166. Guengerich FP,. In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 1998; 24: 521-533.
167. Kan HC, Hollenberg PF, Woolf TF,. Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents. United States Patent 6509731. 2003.
168. Bailey DG, Arnold JMO, Spence JD,. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101-110. (Pubitemid 28342779)
169. Kolars JC, Awni WN, Merion RM, Watkins PB,. First-pass metabolism of cyclosporine by the gut. Lancet 1991; 338: 1488-1490.
170. Lown KS, Bailey DG, Fontana RJ, et al,. Grapefruit juice increases felodipine oral bioavailability in humans by decreasing intestinal CYP3A expression. J Clin Invest 1997; 99: 2545-2553. (Pubitemid 27227734)
171. Paine MF, Widmer WW, Pusek SN, et al., Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am J Clin Nutr 2008; 87: 863-871. (Pubitemid 351549230)
172. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D,. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen elderly study. Lancet 1993; 342: 1007-1011. (Pubitemid 23314801)
173. Reinoso RF, Sanchez Navarro A, Garcia MJ, Prous JR,. Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2002; 24: 593.